Elisigen key facts
as of Oct 2026- Developer of an adeno-associated virus (AAV) gene therapy designed to improve the quality of life of patients.
- Elisigen is valued at approximately $74.5M as of Oct 2026 (last reported valuation).
- It has raised $83.7M; the latest was Later Stage VC ($28.8M) in Jan 2026.
- Notable investors include KB Investment, Korea Investment Partners, Korea Development Bank, Partners Investment, Premier Partners — 24 tracked in total.
- Status: Privately Held (backing).
Elisigen's last reported valuation, Jul 2021. Nothing priced has surfaced since.
- ·The complete investor list: 24 names
- ·Watch Elisigen: the Monday email on marks, rounds and moves
Elisigen funding rounds
No funding rounds for Elisigen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Elisigen
24+Elisigen valuation
Elisigen's last reported valuation was $74.5 million in Jul 2021. No priced round, secondary trade or fund mark has surfaced since.
Elisigen investors
24 investors are on record for Elisigen, including KB Investment, Korea Investment Partners, Korea Development Bank and Partners Investment. By type, the record holds 6 venture capital firms and 1 private equity firm.
About Elisigen
Developer of an adeno-associated virus (AAV) gene therapy designed to improve the quality of life of patients. The company utilizes AAV gene therapy applications for treating neurodegenerative disorders and other intractable and rare diseases, enabling patients to reduce their suffering effectively.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2018
- Employees
- 31
- Website
- elisigen.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.